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 ABSTRACT 
Riboflavin (Rf) receptors bind and translocate Rf and its phosphorylated forms
(e.g. flavin mononucleotide, FMN) into cells where they mediate various cellular
metabolic pathways. Previously, we showed that FMN-coated ultrasmall 
superparamagnetic iron oxide (FLUSPIO) nanoparticles are suitable for labeling
metabolically active cancer and endothelial cells in vitro. In this study, we focused
on the in vivo application of FLUSPIO using prostate cancer xenografts. Size,
charge, and chemical composition of FLUSPIO were evaluated. We explored the
in vitro specificity of FLUSPIO for its cellular receptors using magnetic resonance
imaging (MRI) and Prussian blue staining. Competitive binding experiments
were performed in vivo by injecting free FMN in excess. Bio-distribution of
FLUSPIO was determined by estimating iron content in organs and tumors using
a colorimetric assay. AFM analysis and zeta potential measurements revealed 
a particulate morphology approximately 20–40 nm in size and a negative zeta 
potential (–24.23 ± 0.15 mV) in water. X-ray photoelectron spectroscopy and 
time-of-flight secondary ion mass spectrometry data confirmed FMN present 
on the USPIO nanoparticle surface. FLUSPIO uptake in prostate cancer cells
and human umbilical vein endothelial cells was significantly higher than that of
control USPIO, while addition of excess of free FMN reduced accumulation. 
Similarly, in vivo MRI and histology showed specific FLUSPIO uptake by prostate
cancer cells, tumor endothelial cells, and tumor-associated macrophages. Besides
prominent tumor accumulation, FLUSPIO accumulated in the liver, spleen, lung,
and skin. Hence, our data strengthen our hypothesis that targeting riboflavin
receptors is an efficient approach to accumulate nanomedicines in tumors opening
perspectives for the development of diagnostic and therapeutic systems. 
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1 Introduction 
Vitamins have been studied in the context of diagnostic 
and therapeutic agents because they are biocompatible, 
endogenously accessible, act as carriers, strongly bind 
to respective receptors, and mediate important cellular 
metabolic functions [1–3]. Their pivotal role in the 
prevention and treatment of different types of cancer 
has been explored in various clinical trials, thus 
promoting the development of vitamin-based drugs 
and imaging agents [4, 5]. In this context, a rapid 
translocation of the vitamin-tagged cargo into cancer 
cells was observed via receptor-mediated endocytosis, 
e.g. for folic acid- and riboflavin (Rf)-tagged agents 
[6–12]. In this study, we focused on Rf, an essential 
vitamin that mediates various biochemical, physiologi-
cal, and metabolic (e.g. lipid, carbohydrate) functions 
in cells [13]. Interestingly, cells internalize Rf either  
as flavin mononucleotide (FMN) or flavin adenine 
dinucleotide (FAD), both of which, are vital sources of 
electrons required to facilitate redox reactions linked 
to different metabolic processes [14]. In the plasma and 
the extracellular space, Rf and its metabolic analogues 
(FMN/FAD) bind to a specific carrier protein, Rf carrier 
protein (RCP), shown to be highly expressed on the 
cell surface of metabolically active cells (e.g. prostate 
cancer cells and activated endothelial cells) [15]. Rf 
and the Rf-RCP complex are quickly internalised by 
cells via Rf transporters (RFTs). The rapid and efficient, 
clathrin-mediated endocytosis pathway plays a pivotal 
role in this process [16].  
The biological significance of Rf led us to believe 
that its metabolic analogue, FMN could protect 
ultrasmall superparamagnetic iron oxide (USPIO) 
nanoparticles against oxidative degradation via a 
fluorescent adsorptive coating. Therefore, we designed 
RCP-targeted, fluorescent USPIO (FLUSPIO) as a 
contrast agent for magnetic resonance imaging (MRI) 
and demonstrated its ability to label metabolically 
active cancer cells as well as activated endothelial cells 
[17]. In another previous study, we developed a second 
MRI probe, FAD-USPIO, to assess vascular metabolism 
in prostate tumors [18]. Despite the development   
of these Rf-targeted molecular MRI probes, several 
uncertainties remain, regarding their performance in 
vivo, such as physiological stability (e.g. particle-protein 
interactions), specificity of accumulation, binding to 
tumor and stroma cells, as well as bio-distribution. 
Therefore, in addition to extended physicochemical 
characterization, we focused on the in vivo application 
of FLUSPIO in this study. We investigated the colloidal 
stability in physiological media, plasma protein 
adsorption, bio-distribution and accumulation of 
FLUSPIO in prostate cancer xenografts. 
2 Experimental 
2.1 Materials 
Ferric chloride (FeCl3, >97%), ferrous chloride tetrahy-
drate (FeCl2·4H2O >99%), riboflavin-5′-monophosphate 
sodium salt dihydrate (flavin mononucleotide; FMN, 
73%–79% fluorometric), IDRANAL III® standard 
solution (EDTA-Na2, reagent for metal titration, 0.1 M), 
5-sulfosalicylic acid dihydrate (≥99% for metal 
titration), 4,5-dihydroxy-1,3-benzenedisulfonic acid 
disodium salt monohydrate (Tiron®) indicator, and 
trypan blue solution for microscopy were obtained 
from Sigma Aldrich GmbH (Steinheim, Germany). 
Ammonia (NH3 ≥ 25%), N-(2-Hydroxyethyl)piperazine- 
N′-(2-ethanesulfonic acid) (HEPES, ≥99.5%), hydro-
chloric acid (HCl, 37%), K4[Fe(CN)6], nuclear fast red, 
and hematoxylin and eosin were purchased from Carl 
Roth GmbH (Karlsruhe, Germany). Guanosine-5′- 
monophosphate disodium salt hydrate (GMP, 98%), 
gelatin (ph. Eur. powder), phosphate-buffered saline 
(PBS) (10× Dulbecco’s powder) were procured from 
Applichem (Darmstadt, Germany). Feraspin XS® 
used in this study was provided as a gift sample by 
Miltenyi Biotech GmbH (Bergisch Gladbach, Germany). 
Feraheme® was obtained from AMAG Pharmaceuticals, 
Inc. (Waltham, MA, USA). All chemicals were used 
as received without any further purification. 
2.2 Synthesis of iron oxide nanoparticles (Fe3O4) 
USPIO nanoparticles were synthesized by co- 
precipitation of ferrous (Fe2+) and ferric (Fe3+) salts 
under aqueous alkaline conditions as previously 
described [17, 18]. Briefly, in a stoichiometric ratio of 
2Fe3+:Fe2+, 16 mmol (2.66 g) FeCl3 and 8 mmol (1.63 g) 
FeCl2·4H2O dissolved in 190 mL de-ionized water were 
co-precipitated using 10 mL 25% NH3. The nanoparticles 
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were washed with water and 0.1 M HCl and stored 
under acidic conditions (pH 2) until further use. The 
total iron content (Fe3+ ions) of USPIO (161 mM) was 
determined by titrimetric [19] and colorimetric [20] 
methods.  
2.3 Synthesis of FLUSPIO nanoparticles 
FLUSPIO nanoparticles were prepared as previously 
described [17]. Briefly, 143 mM USPIO (pH 4) was 
sonicated with 35 mM FMN for 1 h at ambient tem-
perature. Subsequently, the FMN-covered nanoparticles 
were washed with water under the influence of high- 
gradient magnetophoresis and then sonicated with 
50 mM GMP for 1 h. After final coating and high- 
gradient magnetophoresis-assisted washing with water, 
the particles were stored at 4 °C until further use.  
2.4 General characterization 
2.4.1 Atomic force microscopy (AFM)  
Samples for AFM analysis were prepared using 
FLUSPIO (5 μL) in water, which were deposited onto 
a polymer membrane (Nucleopore 0.1 μm, Whatman) 
that provided a flat surface to visualize the nano-
particles. Samples were dried in a fume hood for 1.5 h, 
which led to the formation of a ring of dried material 
at the perimeter of the dried droplet, providing a high 
concentration of particle aggregates as a target for 
AFM imaging.   
All AFM images were captured in tapping mode on 
a multimode nanoscope IIIa instrument (Veeco, USA) 
using BudgetSensors Tap300 probes. Topographic and 
phase images were recorded simultaneously from the 
same area of sample.  
2.4.2 Dynamic light scattering (DLS) measurements 
The size distribution of USPIO and FLUSPIO in 10 mM 
HEPES buffer (pH 7.2) with different concentrations of 
human serum albumin (HSA) was investigated by DLS 
using the Malvern Zetasizer, Nano-S (Malvern, UK). 
2.4.3 Zeta potential measurements 
Zeta potential and electrophoretic mobility of USPIO 
and FLUSPIO were determined using a Malvern 4700 
system (Malvern Ltd., Malvern, UK). Freshly prepared 
nanoparticles (0.5 mL) were diluted (1,000-fold) in 
water, 5% (w/v) glucose solution, fetal calf serum (FCS), 
1:1 (v/v) mixture of 5% glucose solution and FCS, or 
25 mM HEPES buffer (pH 7.2), respectively. After 
dilution, each sample was measured on an average of 
seven runs (± the standard deviation) in triplicates. 
Intralipid was used as a reference for zeta potential 
measurements.   
2.4.4 Fluorescence spectroscopy 
The fluorescence spectra of FMN and FLUSPIO su-
spended in different physiologically relevant solutions 
(5% (w/v) glucose solution, FCS alone, and 1:1 (v/v) 
mixture of 5% glucose solution and FCS) were 
recorded for different fluorophore (FMN) and iron 
(FLUSPIO) concentrations ranging from 10–5 to 10–12 
M (37 °C) using the TECAN Infinite M200pro (Tecan 
group, Maennedorf, Switzerland) plate reader.  
2.4.5 Magnetic resonance (MR) relaxometry (phantom 
studies) 
MR relaxometry of FLUSPIO and Feraspin XS® 
(Miltenyi Biotech, Germany), a preclinical MR contrast 
agent for visualizing vasculature, was performed using 
a clinical (3T) whole-body MR scanner (Philips Achieva, 
The Netherlands) in combination with a knee coil 
(SENSE-flex-M, Philips, The Netherlands) at room 
temperature. FLUSPIO and Feraspin XS® were diluted 
in de-ionized water at concentrations ranging from 
0.005 to 50 μg Fe/mL. For MR measurements, 0.3 mL 
diluted FLUSPIO and Feraspin XS® solution was 
filled in custom-made phantoms. For T2 relaxometry 
in phantoms, images were acquired at 20 echo times 
(TE range = 8–180 ms) using a multi-slice, multi-shot, 
spin-echo sequence (1,500 ms TR, 8.1 ms inter-echo 
spacing, 96 × 96 reconstruction matrix size, 2 mm × 
2 mm voxel size, 3-mm slice thickness, 130 mm × 
162.5 mm field of view, 90° flip angle). Regions of 
interest (ROI) were manually defined. T2 relaxation 
times were calculated by a linear fit of the logarithmic 
signal amplitudes versus echo time. 
T1 maps were acquired using a multi-slice, multi- 
shot, fast-field-echo Look-Locker inversion recovery 
sequence using simulated electrocardiogram triggering 
(30 bpm stimulated heart rate, 70-ms phase interval, 
6–8 ms TR, 3–4 ms TE, 160 × 160 reconstruction matrix, 
5-mm slice thickness, 170 mm × 150 mm field of view, 
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10° flip angle). Relaxation signal amplitudes were fitted 
to a signal model to yield T1 relaxation times.  
Relaxivities r1 and r2 for FLUSPIO and Feraspin XS® 
were determined by a linear fit of the inverse relaxation 
times as a function of the iron concentrations. 
2.4.6 Time-of-flight secondary ion mass spectrometry 
(TOF-SIMS)  
TOF-SIMS is a high-vacuum surface technique, which 
provides details about a surface (1–2 nm analysis 
depth) with high chemical sensitivity (ppm). The surface 
chemical composition of USPIO and FLUSPIO samples 
was determined using the Ion ToF IV instrument 
(ION-TOF GmbH, Münster, Germany). Samples were 
prepared as described in the AFM section 2.4.1 above. 
2.4.7 X-ray photoelectron spectroscopy (XPS)  
The quantitative surface elemental composition of 
USPIO and FLUSPIO samples was determined using 
a Kratos Axis Ultra XPS instrument (Kratos Axis Ultra, 
Manchester UK). This technique provides quantitative 
information from a surface analysis depth of 5–10 nm. 
2.4.8 Stability of FLUSPIO in physiological solutions 
The colloidal stability of FLUSPIO suspended in different 
physiologically relevant solutions was checked at 
different settling times. For our study, we suspended 
3.0 μmol Fe/mL FLUSPIO in water, 5% (w/v) glucose 
solution, FCS alone, 1:1 (v/v) mixture of 5% glucose 
solution and FCS, and 25 mM HEPES buffer (pH 7.2), 
respectively. Subsequently, photographs of the colloidal 
suspensions were taken at different time points 
(0, 0.5, 1, 3, 12, and 24 h) using a high-resolution digital 
camera. 
2.5 Cell culture 
LnCap cells were procured from American Type Culture 
Collection (ATCC), USA. Human umbilical vein 
endothelial cells (HUVEC) were obtained from Pro-
mocell GmbH, Heidelberg, Germany. LnCap cells were 
cultured in RPMI medium with Glutamax (Gibco, 
Invitrogen, Germany), 20% FCS (Invitrogen, Germany) 
and 1% Pen/Strep (10,000 U/mL penicillin; 10,000 μg/mL 
streptomycin, Invitrogen, Germany). HUVEC were 
grown in human endothelial cell growth medium 
(VascuLife VEGF, Lifeline Cell Technology, Troisdorf 
Germany) containing growth supplements, 2% FCS 
and 1% Pen/Strep. Cells were cultured in T75 cm2  
cell culture flasks (Cell Star, Greiner, Germany) and 
incubated at 37 °C under 5% CO2 and 95% relative 
humidity conditions until they were confluent. 
2.5.1 Cellular viability testing with trypan blue staining 
The viability of LnCap cells and HUVEC after 
incubation with FLUSPIO was evaluated using trypan 
blue staining (trypan blue solution, Sigma-Aldrich, 
Steinheim, Germany). Cells (2 × 106) were seeded in 
6-well plates (BD Falcon, Germany) and incubated 
overnight. After incubation, medium was removed 
and cells were washed with PBS. Cells incubated with 
cell growth media served as negative controls. The 
positive controls were generated by exposing the 
cells to 90 °C for 10 min. Further control groups were 
maintained under normal growth conditions but after 
adding the coating molecules FMN and GMP to the 
growth medium at different concentrations. USPIO 
and FLUSPIO were diluted in respective cell growth 
media to 0.03, 0.3, 3.0 μmol Fe/mL and cells were 
incubated for 3 and 24 h, respectively. Triplicates per 
condition were analyzed. Subsequently, cells were 
washed, trypsinized (0.25% trypsin/0.05% EDTA) and 
centrifuged. Equal amounts of the cell suspension and 
trypan blue solution were mixed prior to measurement. 
Trypan blue-positive cells (dead cells) were counted 
using a Cedex XS cell counter and the percentage of 
positive cells was reported as a function of the total 
cell count.  
2.6 Competitive binding studies (Prussian blue 
staining) 
To evaluate the specific binding of FLUSPIO to LnCap 
cells and HUVEC, competitive binding studies were 
performed. Cells were seeded on glass slides (76 mm × 
26 mm) placed inside a quadriPERM chamber (Greiner, 
Germany) and incubated overnight to allow them to 
adhere onto the surface. Prussian blue iron staining 
was used to visualize FLUSPIO (0.3 μmol Fe/mL) 
uptake and its inhibition after addition of 10- or 100- 
fold excess of free FMN for 1 h. Additionally, controls 
were carried along where cells were incubated with cell 
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growth medium only or with USPIO (0.3 μmol/mL). 
After incubation for 1 or 3 h, cells were washed thrice 
with PBS and fixed using 4% paraformaldehyde 
solution. Subsequently, the fixed cells were treated 
for 5 min with an aqueous solution of K4Fe(CN)6 (10%) 
and then with a 1:1 mixture of K4Fe(CN)6 (10%) and 
HCl acid (20%) for 30 min. Subsequently, cells were 
counterstained with Nuclear Fast Red (Carl Roth, 
Karlsruhe, Germany). Cover slips were mounted using 
Mowiol medium and cells were analyzed by bright- 
field microscopy (Imager M2, Carl Zeiss Microimaging 
GmbH, Germany) at different magnifications and fields 
of view.  
2.7 MR characterization of competitive binding 
studies 
Specificity of FLUSPIO nanoparticles for Rf receptors 
expressed in LnCap cells and HUVEC was studied 
by MRI through competitive-binding studies. Cells 
were pre-incubated for 10 min with 10-fold excess of 
free FMN. Consecutively, FLUSPIO (0.3 μmol/mL) were 
added and cells were incubated for 1 h at 37 °C. Cell 
growth medium, USPIO (0.3 μmol/mL) and Feraheme® 
(0.3 μmol/mL) were used in control samples under 
comparable conditions. Three samples were analyzed 
per condition. After incubation, cells were washed 
with saline solution and trypsinized by adding 4 mL 
trypsin/EDTA (0.25%/0.05%). Trypsinization was stopped 
by adding respective cell growth media and the cell 
suspension was centrifuged at 1,000 rpm (Multifuge, 
Thermo scientific, Germany) for 5 min. The pellet was 
washed thrice by centrifugation with saline. Cells 
(0.5 × 106 cells/0.3 mL) were suspended in 10% gelatin 
and analyzed by MR-relaxometry as described in 
section 2.4.5.  
2.8 MR imaging of FLUSPIO accumulation in 
LnCap xenografts in mice  
All animal experiments were approved by the 
government review committee on animal care. In this 
study, LnCap tumor xenografts were chosen since 
LnCap cells display high expression of RCP [15]. LnCap 
tumor xenografts were induced by subcutaneous 
injection of 5 × 106 LnCap cells [21] into the right hind 
limb of 10 BALB/c male nude mice (Charles River 
Laboratories International, Inc., Wilmington, MA, 
USA). MR investigations were carried out when tumors 
reached the size of 4 mm × 4 mm (volume of appro-
ximately 33 mm3). The mice (n = 5) were then, 
intravenously injected with 900 μmol Fe/kg FLUSPIO. 
In the competitive-binding group (n = 5), mice were 
injected with 10-fold excess FMN at 10 min before 
FLUSPIO (900 μmol Fe/kg) administration. MR imaging 
of LnCap tumor xenografts pre- and post-particle 
injection (1 and 3 h) was performed under isoflurane 
anesthesia (2%) using a clinical 3T MRI system (Philips 
Achieva 3.0 T), in combination with a custom-built 
small animal solenoid sense-receive mouse coil [17].  
To visualize anatomic details, transverse T2-weighted 
MR images of the tumors were acquired using a 
multi-shot turbo-spin-echo sequence (1,400 ms/100 ms 
(TR/TE), 0.2 mm × 0.2 mm voxel size, 1-mm slice thick-
ness, 144 × 144 reconstruction matrix size, and 25-mm 
field of view). T2*-weighted MR images were acquired 
using a fast-field-echo sequence (117 ms/26 ms (TR/TE), 
0.2 mm × 0.2 mm voxel size, 1-mm slice thickness,  
96 × 96 reconstruction matrix size, 25-mm field of view 
and 30° flip angle). Subsequently, T2* relaxometry was 
performed at the same location using a multi-shot, 
multi-slice fast-field-echo sequence (125 ms/(10–190 ms) 
TR/TE (TE with 15 different echo times), 0.3 mm × 
0.3 mm voxel size, 1-mm slice thickness, 144 × 144 
reconstruction matrix size, 40-mm field of view, 30° 
flip angle and 7.9-ms interval between two echoes). 
Post-processing was performed on the basis of PAR/ 
REC4 images by applying an IDL (version 6.1)-based 
software. Subsequently, color-coded R2* relaxation rate 
pixel maps of tumors were generated using the PRIDE 
analysis software (Philips Healthcare, Germany). 
2.9 Immunohistochemistry and bio-distribution 
2.9.1 Immunofluorescence of LnCap tumors  
LnCap tumor sections (8-μm thickness) were stained 
for endothelial cells (vessels) by incubation with a 
primary rat anti-mouse CD31 (PECAM-1) antibody  
(BD Bioscience, Heidelberg, Germany) for 2 h (room 
temperature), followed by Cy3-labeled anti-rat IgG 
secondary antibody (Dianova GmbH, Hamburg, 
Germany) for 45 min (room temperature). Subsequently, 
different LnCap tumor sections were stained for 
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macrophages using a primary rat anti-mouse CD68 
antibody (AbD Serotec, Duesseldorf, Germany) for 
2 h (room temperature) combined with a Cy3-labeled 
anti-rat IgG secondary antibody for 45 min (room 
temperature). Nuclei in the tumor sections were 
counterstained with DAPI (Merck KGaA, Darmstadt, 
Germany). Fluorescence microscopy analysis (Imager 
M2, Carl Zeiss Microimaging GmbH, Germany) was 
performed at different magnifications (10×, 20×, and 
40×) and fields of view.  
2.9.2 Combined Prussian blue and hematoxylin-eosin (HE) 
staining of LnCap tumors 
Cryo-preserved (–80 °C) LnCap tumors covered with 
Tissue-Tek (O.C.T. Compound, Sakura Finetek Europe 
B.V., Germany) were sectioned and then subjected  
to combined Prussian blue and HE staining. The 
Prussian blue staining protocol was performed as 
described in section 2.6, except that no nuclear fast 
red staining was performed. Subsequently, the tumor 
sections were treated with hematoxylin (Carl Roth 
GmbH, Germany) and with a 1% aqueous solution  
of eosin (Carl Roth GmbH, Germany). Then, tumor 
sections were washed with PBS, dehydrated by 
incubation with an increasing percentage of alcohol 
(70%, 96%, and 100%) and incubated in xylene. Cover 
slips were mounted on the sections using Vitro-Clud 
(R. Langenbrinck, Emmendingen, Germany), a xylene- 
based mounting medium before microscopic analysis 
(Imager M2, Carl Zeiss Microimaging GmbH, Germany).  
2.9.3 Bio-distribution of FLUSPIO in tumor-bearing mice 
For mice (n = 5) injected with FLUSPIO, after MRI 
measurement, liver, spleen, lung, kidney, heart, 
colon, bladder, muscle, and skin as well as LnCap 
tumors were excised and subjected to bio-distribution 
evaluation using an iron-based colorimetric assay. 
The excised organs and tumors were weighed prior 
to dissolving them in 3 mL aqua regia by sonication. 
Subsequently, 1 mL sample solution was diluted in 
water (1:2 and 1:10) and mixed with phosphate buffer, 
4 M NaOH, and 0.25 M Tiron®. The absorbance of the 
iron-tiron complex was measured at 520 nm. Particle- 
related iron uptake was determined by normalizing 
the estimated iron contents to organ weights and by 
subtracting the intrinsic iron content in organs/tumors 
derived from mice that were not administered 
FLUSPIO injections. 
2.9.4 Statistics 
The differences between groups were tested for 
statistical significance using a two-tailed, unpaired 
student’s t-test considering p-values below 0.05 as 
significant. 
3 Results and discussion 
3.1 FLUSPIO synthesis 
USPIO nanoparticles prepared in water are prone to 
oxidative degradation at their surface in the absence 
of a protective coating. In addition, without surface 
functionalization, USPIO uptake by most tissues and 
cells is low, except for those of the reticuloendothelial 
system (RES), which rapidly remove the particles from 
the blood. Therefore, we selected FMN as a specific, 
fluorescent, non-polymeric coating molecule, which 
adsorptively binds to the iron oxide cores via phosphate 
groups (Fig. 1(a)). Adsorptive fluorescent coating was 
accomplished by sonication of USPIO and FMN 
together (pH 4) at ambient temperature. Protecting 
the surface of USPIO nanoparticles with FMN only 
led to partial sedimentation of the particles (visual 
observation) resulting in less-stable suspensions. 
Therefore, to achieve colloidal stability and sustain 
FMN fluorescence without quenching under aqueous 
conditions, the surface of USPIO nanoparticles was 
additionally covered with non-toxic and biocompatible 
GMP. We previously demonstrated that a ratio of 
0.7:0.3 between GMP and FMN molecules is needed 
to expedite complete coverage of USPIO nanoparticle 
surface [17]. Figures S1(a) and S1(b) in the Electronic 
Supplementary Material (ESM) show a schematic 
sketch of the adsorptive coating of USPIO using FMN 
and GMP. Based on the theoretical calculation to 
achieve a monolayer coating of FMN on the USPIO 
nanoparticle surface, 0.004 FMN ligands were required 
per USPIO particle (section S2 in the ESM). In this 
context, further functionalization of the FLUSPIO can 
be achieved by linking small molecules (e.g. peptides, 
therapeutic drugs) either via the free amine at the GMP’s 
guanosine moiety or using suitable spacers (PEG). 
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3.2 FLUSPIO characterization  
The morphology, mean particle size, and size 
distribution of FLUSPIO were studied using AFM, 
and DLS techniques. AFM analysis of USPIO showed  
particles with spherical morphology with a size range 
of 10 to 50 nm (Fig. 1(b)), which conforms to previous 
transmission electron microscopy (TEM)- and scanning 
electron microscopy (SEM)-based size measurements 
[17]. Similarly, AFM analysis of FLUSPIO showed 
 
Figure 1 Physical and chemical characterization of FLUSPIO. (a) The schematic diagram illustrates the adsorptive coating of USPIO
with FMN and GMP via their phosphate groups. (b) and (c) AFM images of USPIO (b) and FLUSPIO (c) where the topography is
shown on the left and phase images on the right. The phase images show spherical surface morphology of FLUSPIO with particles sizes
of 20–40 nm. (d) and (e) Fluorescence spectra of FMN (d) and FLUSPIO (e) measured in 5% glucose solution show emission peaks at
530 nm. The observed reduction in fluorescence intensity of FLUSPIO in comparison to FMN can be due to partial FMN quenching and
competitive interaction of glucose molecules with USPIO surface. (f) and (g) Contrast enhanced MR images of FLUSPIO compared to
commercial iron oxide nanoparticles (Feraspin XS®, core size of 10–20 nm) at different iron concentrations. (f) T2w images reveal 
higher T2 contrast of FLUSPIO than Feraspin XS® in water. (g) In contrast, T1w images display higher T1 MR contrast for Feraspin XS®
than FLUSPIO, which is in line with the manufacturer’s report about its relaxivity. 
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regions of the sample with defined particulate mor-
phology and size ranging from 20 to 40 nm (Fig. 1(c)), 
respectively. TEM-based quantitative size analysis of 
FMN-coated USPIO, achieved after first coating step, 
revealed similar core sizes (5 ± 1 nm) compared to 
final FLUSPIO particles (Figs. S2(a) and S2(b) in the 
ESM).   
Nanoparticles are known to interact with plasma 
proteins in the blood and are subsequently surrounded 
by a protein corona that significantly alters their size, 
charge, and biological behavior. The change in size 
distribution of FLUSPIO nanoparticles after interaction 
with plasma proteins was investigated by DLS. For 
this purpose, FLUSPIO nanoparticles were suspended 
in 10 mM HEPES buffer containing different con-
centrations (% w/v) of HSA. DLS measurements of 
FLUSPIO in the presence of HSA revealed sizes of 109 ± 
6 (0.04% HSA), 107 ± 4 (0.4% HSA), and 134 ± 2 nm 
(4.0% HSA) with a polydispersity index of 0.31. The 
size increase of FLUSPIO nanoparticles in presence of 
4.0% HSA can be explained by adsorption of plasma 
proteins [22, 23] forming a protein corona and by 
non-specific and weak binding of HSA to Rf [24]. 
Zeta potential measurements were performed to 
determine the surface charge, electrophoretic mobility, 
and colloidal stability of USPIO and FLUSPIO in 
different physiological solutions. USPIO showed 
negative zeta potentials in FCS, FCS mixed with 5% 
glucose (1:1) and HEPES buffer, but positive values in 
5% glucose solution and water (Table 1). In comparison 
to USPIO nanoparticles, zeta potentials of FLUSPIO 
nanoparticles were more negative in all solutions 
(always < 10). Lowest values were observed in 5% 
glucose solution, followed by water, HEPES buffer, 
5% glucose solution with FCS, and FCS alone, which 
implies colloidal stability under physiological conditions 
(Table 1). In this context, the higher zeta potentials  
in FCS and in the 1:1 mixture of 5% glucose and FCS  
indicate some amount of loss in stability due to 
non-specific protein adsorption as described above. 
However, it is important to note that binding of 
soluble RCP to FLUSPIO, may even be beneficial for 
cellular targeting and uptake [25]. 
3.3 Fluorescence properties of FLUSPIO  
Free FMN suspended in different physiological 
solutions at varied concentrations revealed intense 
emission at 530 nm. Highest fluorescence intensity 
was observed with 5% glucose at 37 °C (Fig. 1(d)) as 
compared to FCS alone and 5% glucose/FCS (1:1) 
solutions (Figs. S3(a) and S3(b) in the ESM). The partial 
reduction of fluorescence in protein solutions could 
be due to non-specific association between FMN and 
serum proteins [26]. 
Surprisingly, in contrast to free FMN, FLUSPIO 
fluorescence was not affected when suspended in FCS 
or 5% glucose/FCS (1:1) solution (Fig. 1(e) and Figs. S3(c) 
and S3(d) in the ESM). This can be related to con-
formational changes in FMN on the surface of FLUSPIO 
nanoparticles, reducing non-specific interaction of 
FMN with FCS. These stable fluorescent properties 
are highly beneficial, in particular, when considering 
FLUSPIO for longitudinal cell-labeling studies and 
for fluorescence-based histological analysis. 
3.4 Magnetic properties of FLUSPIO  
The MR relaxivity and contrast enhancement properties 
of FLUSPIO suspended in de-ionized water at different 
iron concentrations were determined and compared 
to the commercial MR contrast agent, Feraspin XS®, 
which has a similar core size (Figs. 1(f) and 1(g)). 
FLUSPIO (r2 = 368.0 ± 1.24 s–1·mM–1) was characterized 
by a higher T2 relaxivity than Feraspin XS® (r2 = 
63.06 ± 0.37 s–1·mM–1). The higher T2 relaxivity of 
FLUSPIO than Feraspin XS® can be attributed to the  
Table 1 Zeta potentials of USPIO and FLUSPIO suspended in different solutions 
Zeta potential (mV)  
Nanoparticles Water 5% (w/v)    
glucose solution 
FCS 1:1 (v/v) glucose 
solution and FCS 
HEPES buffer 
USPIO 40.70 ± 1.65 29.73 ± 1.46 –6.37 ± 0.29 –8.57 ± 0.34 –3.76 ± 0.29 
FLUSPIO –24.23 ± 0.15 –25.63 ± 0.60 –10.83 ± 0.25 –11.03 ± 0.71 –23.60 ± 2.06 
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formation of nanoclusters during FMN coating, which 
is reflected by its increased hydrodynamic size. In 
contrast, the T1 relaxivity of Feraspin XS® (r1 = 6.25 ± 
1.41 s–1·mM–1) was higher than that of FLUSPIO (r1 = 
3.97 ± 1.37 s–1·mM–1), as expected. Therefore, due to 
high r2 relaxivity and T2 contrast enhancement, 
FLUSPIO may be useful for T2-based MR cell labeling, 
cell tracking, and molecular imaging applications, 
rather than for T1-weighted imaging. 
3.5 Chemical composition and colloidal stability of 
FLUSPIO 
The chemical composition of USPIO and FLUSPIO 
surface was analyzed by TOF-SIMS and XPS techni-
ques. TOF-SIMS provides molecular and chemical 
information about the outer 1–2 nm of the particle 
surface. Figures 2(a) and 2(b) compares some key 
molecular fragments between the USPIO and FLUSPIO  
 
Figure 2 Investigation of surface composition and physiological stability of FLUSPIO in different solutions. (a) and (b) TOF-SIMS
spectra of USPIO (a) and FLUSPIO (b) confirm the presence of adsorptive molecules (respective fragmentation peaks) on FLUSPIO
surface compared to USPIO displaying no prominent fragmentation peaks. (c) Elemental composition of USPIO and FLUSPIO
determined by XPS showed an increase in percentages of carbon, nitrogen, and phosphorous on FLUSPIO surface compared to USPIO,
which is in line with the TOF-SIMS data. (d) Digital photographs of FLUSPIO (3.0 μmol Fe/mL) suspended in physiological solutions
such as H2O (A), 5% glucose solution (B), FCS alone (C), 1:1 (v/v) mixture of 5% glucose solution and FCS (D), and 25 mM HEPES
buffer (pH 7.2) (E), at different settling times (0, 0.5, 1.0, 3.0, 12.0, and 24.0 h), respectively. FLUSPIO exhibited good stability in all
solutions for up to 1 h and in all solutions except for 5% glucose, for up to 24 h. 
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samples. Some peaks are only present in FLUSPIO, 
which are related to phosphate chemical functionality. 
The higher mass peaks shown in Fig. 2(b) relate directly 
to molecular fragments from the coating composition 
(insert in Fig. 2(b)). 
Comparison of the elemental surface composition 
obtained by XPS measurements (Fig. 2(c)) shows a 
clear difference between the uncoated USPIO and 
coated FLUSPIO nanoparticles. The increase in carbon, 
nitrogen, and phosphorous in FLUSPIO compared to 
USPIO confirms the successful adsorptive coating 
with FMN and GMP. Due to the analysis depth of the 
technique (5–10 nm), there is still a remnant iron signal 
visible from the FLUSPIO sample (Fig. 2(c)).  
The colloidal stability of FLUSPIO (3.0 μmol Fe/mL) 
suspended in various physiological solutions (water, 
5% glucose solution, FCS alone, 1:1 mixture of 5% 
glucose solution and FCS, and HEPES buffer) was 
visualized through digital photographs at different 
settling times (0, 0.5, 1, 3, 12, and 24 h) (Fig. 2(d)).  
The photographs indicate colloidal stability without 
sedimentation of FLUSPIO except for 5% glucose 
until 24 h (Fig. 2(d)). 
The sedimentation rate in 5% glucose solution was 
consistent with previous results [17]. Of note, a lower 
dosage of FLUSPIO (e.g., 0.9 μmol Fe/mL) in 5% 
glucose was used for in vivo application in this study 
and the suspension was immediately injected into the 
blood.  
One of the other physiological solutions evaluated 
in this study will be selected for further study, via 
systemic administration of FLUSPIO in vivo.   
3.6 Cytotoxicity assay  
The biocompatibility of FLUSPIO with LnCap cells 
and HUVEC was evaluated by trypan blue staining. 
As shown in Figs. S4(a)–S4(d) in the ESM, trypan blue 
staining indicated no significant reduction in cell 
viability of both cell types until 24 h, at labeling con-
centrations of up to 0.3 μmol Fe/mL. Consistent with 
these results, another previous study showed that 
even high FLUSPIO concentrations do not negatively 
affect cellular proliferation and integrity or induce 
major oxidative stress [27].  
3.7 Competitive binding studies (Prussian blue 
staining and MRI)  
The cellular uptake of FLUSPIO by prostate cancer 
(LnCap) and activated endothelial cells (HUVEC) 
was studied using Prussian blue staining, where 
internalized FLUSPIO were visible as blue granules 
in the cytoplasm of the cells. After incubation of 
LnCap cells with FLUSPIO for 1 h stronger uptake of 
FLUSPIO (0.3 μmol Fe/mL) than USPIO was observed 
(Fig. 3(a)). HUVEC incubated for 1 h with FLUSPIO 
showed even higher uptake than LnCap cells (Fig. 3(a)). 
This trend persisted and was also visible when the 
incubation time was increased to 3 h (Figs. S5(a)–S5(f) 
in the ESM). The higher uptake by HUVEC than LnCap 
cells might be due to cell type-specific characteristics 
and increased metabolic activity linked to elevated 
Rf-transporter expression [28]. Thus, we speculate 
that in vivo, FLUSPIO mostly labels the endothelial 
layer of angiogenic blood vessels prior to their entry 
into the tumor tissue.  
Furthermore, after 1 h of incubation, the competitive 
inhibition of FLUSPIO uptake by LnCap cells and 
HUVEC by addition of 10- and 100-fold excess FMN 
was visualized by Prussian blue staining (Fig. 3(a)) 
and confirmed their target specificity.  
Subsequently, we used MR Relaxometry to quantify 
the cellular internalization of FLUSPIO and the 
specificity of its uptake (Fig. 3(b)). For these experi-
ments, LnCap cells were used, which are more 
uniform and easy to handle than primary cultures of 
endothelial cells. Furthermore, LnCap cells have been 
described to display the highest RCP levels among all 
prostate cancer cells tested so far [15].  
After incubation with FLUSPIO, LnCap cells showed 
a significantly higher R2 relaxation rate (11.29 ± 1.64 s–1, 
p < 0.001) compared to cells incubated with USPIO 
(2.88 ± 0.41 s–1) and Feraheme® (1.83 ± 0.26 s–1) 
indicating higher cellular internalization of FLUSPIO. 
After adding 10-fold excess of free FMN and 
subsequent incubation with FLUSPIO for 1 h, the  
R2 relaxation rates were significantly lower (6.38 ± 
0.66 s–1, p < 0.05) compared to FLUSPIO alone (11.29 ± 
1.64 s–1) (Fig. 3(b)). This indicates that the uptake of 
FLUSPIO is mediated by Rf receptors. We have further 
 www.theNanoResearch.com∣www.Springer.com/journal/12274 | Nano Research 
1329 Nano Res. 2016, 9(5): 1319–1333 
validated the specific uptake of FLUSPIO in HUVEC 
that served as a model of angiogenic endothelium. 
HUVEC labeled with FLUSPIO displayed significantly 
higher relaxation rates (14.15 ± 2.83 s–1, p < 0.005) 
compared to USPIO (2.11 ± 0.39 s–1) and Feraheme® 
(0.57 ± 0.06 s–1) (Fig. 3(c)) at incubation conditions 
analogous to LnCap. In line with the results from 
histological evaluation, the uptake of FLUSPIO by 
HUVEC was higher than that by LnCap cells. The 
uptake of FLUSPIO by HUVEC was also reduced 
after blocking the receptors with 10-fold excess FMN. 
The relaxation rate of HUVEC incubated with FLUSPIO 
was 14.15 ± 2.83 s–1, whereas with FLUSPIO and FMN, 
a value of 10.11 ± 1.96 s–1 was achieved (Fig. 3(c)). 
Taken together, MR relaxometry results show stronger 
uptake of FLUSPIO by angiogenic endothelial cells 
than prostate cancer cells (LnCap), consistent with 
results from Prussian blue staining. 
Although the specificity of uptake was proven for 
both cell types, the exact uptake mechanism is still 
unclear. The function of Rf receptors is complex since 
Rf transporters (RFTs [29–32]) in the cell membrane 
internalize free Rf as well as the complex of Rf and its 
carrier protein RCP. There is a hypothesis that uptake 
of the latter occurs via clathrin-mediated endocytosis, 
which is one of the fastest and most efficient inter-
nalization pathways for nanoparticles [16]. In this 
context, the impact that RCP and its complexation 
with FMN on the FLUSPIO nanoparticle surface  
had on cell uptake is unclear and is part of ongoing 
research. 
3.8 In vivo uptake of FLUSPIO nanoparticles 
Mice injected with FLUSPIO (900 μmol Fe/kg) com-
prised the specific group (n = 5), whereas those injected 
with 10-fold excess FMN followed by FLUSPIO 
 
Figure 3 Cellular uptake and specificity of FLUSPIO as studied by Prussian blue staining and MRI. (a)–(c) Prussian blue images of 
LnCap and HUVEC after 1 h incubation with cell growth media, USPIO (0.3 µmol Fe/mL) and 0.3 µmol Fe/mL of FLUSPIO. The 
uptake of FLUSPIO is visualized by blue granules in the cytoplasm of the cells and higher for FLUSPIO than USPIO in HUVEC and
LnCap cells. Furthermore, the uptake of FLUSPIO is higher in HUVEC than in LnCap cells. The specificity of the FLUSPIO for Rf
receptors expressed by LnCap cells and HUVEC is indicated by competitively inhibiting their uptake with 10- and 100-fold excess of 
FMN (a). Scale bar: 50 µm. (b) and (c) Results from MR relaxometry: The uptake of FLUSPIO by LnCap cells (b) and HUVEC (c) was
significantly higher (** p < 0.005, *** p < 0.001) for FLUSPIO than USPIO and Feraheme® (all particles: 0.3 µmol Fe/mL). The specificity 
of FLUSPIO uptake is indicated by reduced R2 relaxation rates after competitively blocking the receptors with 10-fold excess of free 
FMN (* p < 0.05). 
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comprised the competitive-binding group (n = 5). At     
1 and 3 h post-intravenous injection of FLUSPIO, a 
significantly stronger increase in R2* relaxation rates 
was observed in prostate cancer xenografts of the 
specific than the competitive-binding group (FLUSPIO 
vs. competition at 1 h: 22.28 ± 7.22 s–1 versus 6.18 ± 
3.84 s–1, p < 0.005; at 3 h: 18.78 ± 5.80 s–1 versus 7.72 ± 
3.57 s–1, p < 0.05) (Fig. 4(g)). These changes in R2* 
relaxation rates are clearly visible in the color-coded 
R2* pixel maps overlaid on T2*-weighted images 
(Figs. 4(a)–4(f)), proving that the concept of Rf-based 
tumor targeting with nanoparticles is successful in 
vivo. The chosen experimental time points were early 
since FLUSPIO nanoparticles display a short circulation 
time of only 30 min (unpublished data). Thus, the 
passive accumulation of FLUSPIO via the “Enhanced 
Permeability and Retention” (EPR) effect is low, which 
is advantageous for molecular imaging purposes but 
not optimal to maximize particle accumulation in the 
tumors, as required for therapeutic nanomedicines. 
 
Figure 4 In vivo accumulation and competitive binding experiments using LnCap tumor xenografts, as analyzed by MRI and 
immunohistochemistry. (a)–(f): The R2* color-coded pixel maps were overlaid on T2*-weighted MR images (transversal slice) of LnCap 
tumors (n = 5) pre- and post-intravenous injection (1 and 3 h) of FLUSPIO ((a)–(c), specific group) and 10-fold FMN + FLUSPIO 
((d)–(f), competition group), respectively. The increase in R2* relaxation rate after FLUSPIO injection (g) is shown by an increase in red
color in the color-coded pixel map ((b) and (c)). Significantly less accumulation (g) is observed in the competitive binding group ((e) 
and (f)). * p < 0.05, ** p < 0.005. Triple fluorescence images ((h), (i), (l), and (m)) (cell nuclei, DAPI: blue, endothelial cells, CD31:
red, FLUSPIO: green) show highly vascularized tumors and FLUSPIOs’ localization inside (yellow) and outside of the endothelium of 
tumor blood vessels, which is in line with Prussian blue- (j) and Prussian blue/HE-stained (k) images. The triple fluorescence (l) and 
Prussian blue/HE-stained images of LnCap tumors from the competitive binding group revealed lower accumulation of FLUSPIO ((n) 
and (o)). There was also particle uptake by macrophages (red, CD 68) in tumors of the FLUSPIO group (yellow signals in (i)), which
was reduced by competitive blocking (m). Together, these results clearly show accumulation of FLUSPIO nanoparticles in endothelial
cells, tumor associated macrophages, and tumor cells as well as their in vivo specificity for RCP. Scale bar: 50 µm. 
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For this purpose FLUSPIO will need modifications 
using appropriate ligands (e.g. PEG). 
3.9 Immunohistological assessment of in vivo 
accumulation of FLUSPIOs 
LnCap tumor sections derived from the FLUSPIO 
and competitive-binding groups were used for 
immunofluorescence (IF) and histology-based validation 
of MR findings. Tumor vessels were stained for CD31 
(red) and nuclei were counter-stained with DAPI (blue). 
Triple-fluorescence images of the LnCap tumor sections 
show localization of FLUSPIO (green) (Fig. 4(h)) pre-
dominantly inside the endothelium but also outside 
of the angiogenic blood vessel (Fig. 4(h)). IF images 
of the competitive-binding group show significantly 
less FLUSPIO accumulation in the tumors, indicating 
that the particle accumulation is not just related    
to the EPR effect (Fig. 4(l)). Prussian blue images are 
consistent with IF images and additionally indicate 
that entire FLUSPIO nanoparticles and not just desorbed 
FMN or USPIO were accumulated in the tumors 
(Figs. 4(j), (k), (n), and (o)).  
To further investigate distribution of FLUSPIO 
inside the tumors, macrophages were stained using 
an anti-CD68 antibody. Triple fluorescence images of 
FLUSPIO, cell nuclei, and macrophages indicated 
FLUSPIO uptake by tumor-resident macrophages (red) 
(Fig. 4(i)). Since FLUSPIO uptake by macrophages 
was lower in the competitive-binding group (Fig. 4(m)), 
uptake by macrophages seems to depend—at least 
partially—on Rf receptors and not just on unspecific 
phagocytic activity.  
3.10 Bio-distribution of FLUSPIO 
As anticipated from previous studies on USPIO bio- 
distribution, there was a strong uptake of FLUSPIO by 
organs of the reticuloendothelial systems, in particular 
the liver and spleen [33, 34]. Further, its accumulation 
in the lung can be explained by macrophage uptake. 
The signals in kidney and bladder may derive from a 
fraction of very small particles (<5 nm) or iron remnants 
that are small enough to be filtrated. The presence of 
particles in the colon is the consequence of the mainly 
hepatobiliary elimination. High accumulation of Rf- 
receptor targeted particles in the skin was found for  
 
Figure 5 Bio-distribution of FLUSPIO in LnCap tumor xenografts 
as evaluated by iron colorimetry. 
all Rf-based probes that we tested so far and is most 
probably related to the known high expression of  
Rf receptors in this organ [35]. Thus, targeting this 
organ can be considered as a further indication for 
RFT-targeted nanoparticles and drugs. On the other 
hand, in safety evaluations of RFT-targeted probes 
particular care has to be taken not to oversee adverse 
side effects in the skin. The strong accumulation in 
the tumor can be explained by FLUSPIO binding to 
tumor cells, which highly express Rf-receptors and by 
the binding of FLUSPIO to the cancer related stromal 
cells, in particular to the endothelial cells and to the 
tumor macrophages. 
4 Conclusions 
In summary, we showed that Rf receptor-mediated 
targeting is an efficient way to accumulate nano-
particles in prostate cancer cells. High levels of FLUSPIO 
accumulation in the tumors can be explained by its 
ability to target both, the tumor cell and the stromal 
compartment, of macrophages and angiogenic endo-
thelial cells. Furthermore, our bio-distribution data 
indicate that besides the expected nanoparticle uptake 
by organs of the RES, the skin shows enhanced 
accumulation that can be related to high Rf receptor 
expression. Nevertheless, further and more detailed 
studies will be required to better understand the 
regulation of the Rf receptor expression in healthy 
and pathologically altered tissues before it can be 
considered as a target for diagnostic and therapeutic 
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probes. In this context, motivated by our results with 
FLUSPIO, an investigation of other flavin-tagged carrier 
systems (e.g. liposomes and polymers) for diagnostic, 
therapeutic, and theranostic applications is underway.  
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